

Drug Pipeline MONTHLY UPDATE

Critical updates in an ever changing environment

March 2020

NEW DRUG INFORMATION

- **Anjeso™ (meloxicam IV):** The U.S. Food and Drug Administration (FDA) approved Baudax Bio's Anjeso for the treatment of moderate-to-severe pain. Anjeso has 30mg of meloxicam per mL and is health care administered as a once-daily intravenous bolus injection. Anjeso was approved based on two Phase 3 trials that evaluated postoperative pain in patients compared to placebo. Results demonstrated statistically significant reduction in the pain, based on the numeric pain rating scale (NPRS: baseline of 6.8) as the primary end point over the first 48 hours.¹ Approval came after two complete response letter (CRL) denials from the FDA concerning onset and duration of the medication. Baudax Bio plans on launching Anjeso in late April or early May 2020 with a cost of \$94 per treatment.²
- **Twirla™ (ethinyl estradiol and levonorgestrel transdermal system):** Agile Therapeutics' Twirla received an FDA approval as a low dose contraceptive patch for the prevention of pregnancy. Twirla is a once weekly patch that Agile Therapeutics states should help increase patient compliance. As part of Twirla's approval, the FDA is requiring Agile Therapeutics to conduct a long-term prospective study comparing the risks for venous thromboembolism (VTE) and arterial thromboembolism (ATE) in new users of Twirla versus other combined hormonal contraceptives. The final study report for the Twirla study is scheduled to be submitted to the FDA in November 2032, with interim safety data reporting in November 2026. The FDA has requested additional post-marketing commitment from Agile Therapeutics to assess the residual drug content and strength.³ Currently, the only other transdermal patch available on the market is the generic version of Ortho Evra, Xulane®, that delivers 150mcg of a different progestin, norelgestromin, and 35mcg of ethinyl estradiol per day.⁴ Twirla is set to launch in fourth quarter 2020 with pricing to follow.⁵
- **Vyepti™ (eptinezumab-jjmr):** The FDA approved Adler BioPharmaceuticals' Vyepti for the prevention of migraine. Vyepti is the first intravenous calcitonin gene-related peptide (CGRP) (compared to available subcutaneous CGRPs) that is used as preventive migraine treatment, which should be administered once every three months. Vyepti's approval is based off two clinical trials, PROMISE-1 and PROMISE-2, which measured the frequency of migraines patients had compared to baseline. The clinical trials demonstrated a treatment benefit over placebo that was observed for both doses (100mg, 300mg) of Vyepti. PROMISE-1 demonstrated that Vyepti decreased migraine days by three to four days per month compared to baseline. PROMISE-2 demonstrated Vyepti reduced migraine days by seven to eight days per month compared to baseline.⁶ Adler BioPharmaceuticals plans to launch Vyepti in April 2020 with wholesale acquisition cost (WAC) of \$5,980 per year.⁷

- **Nexletol™ (bempedoic acid):** Esperion Therapeutics' Nexletol has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Nexletol is a first-in-class ATP citrate lyase inhibitor. In the past few years, there has been excitement over PCSK9 monoclonal antibodies for the treatment of cholesterol, however these agents are delivered subcutaneously and are very expensive. The FDA-approved Nexletol, based on Phase 3 study, demonstrated an average of 18% reduction of LDL-C when used with moderate or high intensity statins, compared with placebo.⁸ Esperion Therapeutics plan to launch Nexletol on March 30, 2020 with a wholesale acquisition cost (WAC) of \$10 per day.⁹
- **Nexlizet™ (bempedoic acid and ezetimibe):** Esperion Therapeutics' Nexlizet has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Nexlizet was approved based on the Phase 3 Fixed Combination Drug Product lowering program, as well as safety data from the bempedoic acid tablet Phase 3 trial. Nexlizet lowered LDL-C by a mean of 38% compared to placebo when added on to maximally tolerated statins.¹⁰ Esperion Therapeutics plan to launch Nexlizet in July 2020 with a WAC of \$10 per day.
- **Barhemsys™ (amisulpride):** The FDA has approved Acacia Pharma's Barhemsys for post-operative nausea and vomiting who are symptomatic despite having received prophylactic treatment. Barhemsys is an intravenous selective dopamine antagonist that can be used as prophylaxis or treatment as a single agent or in combination. The FDA approved Barhemsys based on four Phase 3 studies of more than 3,300 people. The studies demonstrated Barhemsys 10mg dose alone was significantly more effective at reducing post-operative nausea and vomiting compared to placebo (42% vs. 29%) and Barhemsys 5mg dose in combination with another antiemetic significantly reduced nausea and vomiting compared to placebo (58% vs 47%).¹¹ Acacia Pharma plans to launch Barhemsys in the second half of 2020 with pricing to follow.
- **Nurtec ODT™ (rimegepant):** Biohaven's Nurtec orally disintegrating tablet (ODT) was approved by the FDA for treatment of acute migraine. Nurtec ODT is not for preventive migraine. Nurtec ODT is the only fast-dissolving formulation of the calcitonin gene-related peptide (CGRP) receptor antagonist class. Nurtec ODT, 75mg, can be taken without water and delivers pain relief within one hour, with sustained efficacy up to 48 hours.¹² The FDA approved Nurtec ODT based on two Phase 3 clinical trials that demonstrated freedom from most bothersome symptoms at two hours post dose compared to placebo. Eighty-six percent of patients treated with Nurtec ODT did not require rescue medications within 24 hours post dose. In January 2020 the Institute for Clinical and Economic Review (ICER) evaluated CGRP receptor antagonist class and found Eli Lilly's Reyvow® (lasmiditan), Biohaven's Nurtec® (rimegepant) and Allergan's Ubrelvy® (ubrogepant) all perform better than placebo, but evidence is not adequate to distinguish among them. For acute migraines, ICER states generic triptans would be the most effective and cost effective.¹³ Biohaven launched Nurtec ODT in March 2020, available in blister packs of eight tablets, with a WAC of \$4,200-\$4,600 annually.¹⁴

- **Durysta™ (bimatoprost sustained release implant):** Allergan's Durysta has been approved by the FDA for reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Durysta is a biodegradable intracameral implant that is limited to a single implant per eye and should not be re-administered to an eye previously treated with Durysta due to possible corneal endothelial cell loss. The FDA approved Durysta based on two Phase 3 studies of Durysta versus twice daily topical timolol 0.5% drops. Durysta reduced IOP by approximately 30% from baseline over the 12-week primary efficacy period (approximately 5-8mmHg in patients with a mean baseline IOP of 24.5mmHg) compared to competitor.¹⁵ Bimatoprost is available generically as an ophthalmic solution for the same indication as Allergan's Durysta™ (bimatoprost sustained release implant). Launch and pricing pending.

GENERIC DRUG INFORMATION

- **Camptosar inj® (irinotecan inj)+:** Areva Pharmaceuticals has launched its generic version of Pfizer's Camptosar injection for treatment of colorectal cancer. There are no longer any regulatory exclusivities. Camptosar generated \$10 million in U.S. annual sales in 2018.
- **Metastron inj® (strontium-89 chloride inj)+:** Biomed has launched its generic version of GE Health Care's Metastron injection for treatment of bone pain in patients with skeletal metastases. Annual sales for Metastron are unknown.
- **Phenobarbital inj® (phenobarbital inj):** Cameron Pharmaceuticals launched its version of Hikma's Phenobarbital injection used as an anticonvulsant. Phenobarbital injection annual sales are unknown.
- **Vimovo® (naproxen/esomeprazole DR):** Dr Reddy's launched its version of Horizon Therapeutics' Vimovo for treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Multiple manufacturers are set to launch in 2020. Vimovo generated \$578 million in U.S. annual sales in 2018.
- **Dymista® (azelastine/fluticasone nasal spray):** Apotex launched its version of Mylan's Dymista for treatment of seasonal allergic rhinitis. Apotex is eligible for 180-day exclusivity. Multiple manufacturers are set to launch their generic versions of Dymista in August 2020. Dymista generated \$141 million in U.S. annual sales in 2018.
- **Geodon® (ziprasidone inj):** Gland Pharma launched its version of Pfizer's Geodon injection for the treatment of schizophrenia. There are no longer any regulatory exclusivities on Geodon. Geodon injection generated \$23 million in U.S. annual sales in 2018.
- **Dotarem® (gadoterate meglumine, IV soln):** GE Healthcare launched its version of Guerbet's Dotarem as a contrast agent. There are no further exclusivities on Dotarem. Dotarem generated \$123 million in U.S. annual sales in 2018.
- **Zortress® (everolimus)+:** Hikma launched its version of Novartis' Zortress for prophylaxis of organ rejection. Two other manufacturers are awaiting approval for their generic versions of Zortress. Zortress generated \$146 million in U.S. annual sales in 2018.

+Specialty medication

NEW MOLECULAR ENTITY APPROVALS IN THE PAST TWELVE MONTHS

GENERIC NAME	BRAND NAME	MANUFACTURER	INDICATION(S)	DATE APPROVED*
rimegepant	Nurtec ODT™	Biohaven	Acute Migraine	February 2020
eptinezumab-jjmr	Vyepti™	Adler BioPharmaceuticals	Migraine prevention	February 2020
amisulpride	Barhemsys®	Acacia Pharma	Post-operative nausea and vomiting	February 2020
bempedoic acid	Nexletol®	Esperion Therapeutics Inc	High cholesterol	February 2020
lumateperone	Caplyta®	Intra-Cellular Therapies	Schizophrenia	December 2019
lemborexant	Dayvigo®	Eisai/Prudue Pharma	Insomnia	December 2019
ubrogepant	Ubrelvy®	Allergan	Acute Migraine	December 2019
cenobamate	Xcopri™	SK Biopharmaceuticals	Antiepileptic	November 2019
asenapine	Secuado™	Noven Pharmaceuticals	Schizophrenia	October 2019
lasmiditan	Reyvow®	Lilly	Acute Migraine	October 2019
tenapanor	Ibsrela®	Ardelyx	IBS-C	September 2019
istradefylline	Nourianz™	Kyowa Kirin	Parkinson's disease 'off' episodes	September 2019
pitolisant	Wakix™	Harmony	Narcolepsy	August 2019
imipenem, cilastatin and relebactam	Recarbrio™	Merck	Complicated UTI and infections	July 2019

*Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product's manufacturer.

OTHER NEW PRODUCT APPROVALS IN THE PAST TWELVE MONTHS

GENERIC NAME	BRAND NAME	MANUFACTURER	INDICATION(S)	DATE APPROVED*
bimatoprost sustained-release (SR)	Durysta™	Allergan	Open-angle glaucoma or ocular hypertension	February 2020
bempedoic acid/ezetimibe	Nexlizet™	Esperion Therapeutics	High cholesterol	February 2020
semaglutide, oral tablet	Rybelsus™	Novo Nordisk	Diabetes	February 2020
ethinyl estradiol and levonorgestrel transdermal system	Twirla™	Agile Therapeutics	Pregnancy prevention	February 2020
meloxicam IV	Anieso™	Baudax Bio	Pain	February 2020
lactitol	Pizensy™	Braintree Laboratories Inc.	Chronic idiopathic constipation	February 2020
empagliflozin, linagliptin and metformin XR	Trijardy XR™	Boehringer Ingelheim and Eli Lilly	Type 2 diabetes	January 2020
fidaxomicin	Dificid™	Merck	Clostridium difficile-associated diarrhea (CDAD)	January 2020
ferric derisomaltose	Monoferric™	Pharmacosmos	IV iron replacement product	January 2020
tazarotene	Arazlo™	Ortho Dermatologics	Acne vulgaris	January 2020
diazepam	Valtoco™	Neurelis	Seizures	January 2020
levamlodipine tablets	Conjupri™	Conjupro Biotherapeutics, Inc.	Hypertension	December 2019
cefiderocol	Fetroja™	Shionogi	Complicated urinary tract infections (cUTI)	November 2019
rifabutin, amoxicillin and omeprazole	Talicia™	RedHill	Helicobacter pylori	November 2019
minocycline foam 4%	Amzeeq™	Foamix Pharmaceuticals	Acne vulgaris	October 2019
cetirizine, injectable	Quzyttir™	JDP Therapeutics	Acute urticaria	October 2019
trifarotene cream	Aklief™	Galderma Laboratories	Acne	October 2019
dexamethasone	Hemady™	Dexcel	Multiple Myeloma	October 2019
baclofen	Ozobax™	Metacel Pharmaceuticals	Muscle relaxant	September 2019
fosaprepitant	Fosaprepitant™	Teva	Chemotherapy-induced nausea and vomiting	September 2019
glucagon injection	Gvoke™	Xeris Pharmaceuticals	Severe hypoglycemia in diabetes	September 2019
metformin HCl for extended-release oral suspension	Riomet ER®	Sun Pharma	Type 2 diabetes	September 2019
semaglutide	Rybelsus®	Novo Nordisk	Type 2 diabetes	September 2019
ferric maltol	Accrufer™	Shield Therapeutics	Iron deficiency	July 2019
nasal glucagon	Bagsimi™	Lilly	Hypoglycemia	July 2019
duloxetine DR	Drizalma Sprinkle™	Sun	Depression, anxiety, and neuropathic pain	July 2019

continued

OTHER NEW PRODUCT APPROVALS IN THE PAST TWELVE MONTHS *(continued)*

GENERIC NAME	BRAND NAME	MANUFACTURER	INDICATION(S)	DATE APPROVED*
amlodipine benzoate suspension	Katerzia™	Silvergate Pharms	Hypertension	July 2019
tiopronin DR	Thiola EC™	Mission Pharmacal/ Retrophin	Cystinuria	July 2019
budesonide	Ortikos™	Sun Pharma	Crohn's disease	June 2019
drospirenone	Slynd™	Exeltis	Pregnancy prevention	June 2019
dapagliflozin, saxagliptin and metformin hydrochloride	Qternmet XR™	AstraZeneca	Type 2 diabetes	May 2019
midazolam	Nayzilam™	UCB and proximagen	Seizures	May 2019
halobetasol propionate and tazarotene	Duobrii™	Ortho Dermatologics (Valeant)	Plaque psoriasis	April 2019
ivabradine solution	Corlanor™	Amgen	To reduce the risk of hospitalization for worsening heart failure in pediatric patients	April 2019
dolutegravir and lamivudine	Dovato™	Viiv Healthcare	HIV	April 2019
colesevelam hydrochloride	Welchol™	Daiichi Sankyo, Inc	High cholesterol and type 2 diabetes	April 2019

*Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product's manufacturer.

PIPELINE WATCH

GENERIC NAME	BRAND NAME	MANUFACTURER	INDICATION(S)	DATE APPROVED*
risperidone, extended-release injection	Rykindo™	Luye Pharma Group	Schizophrenia and bipolar disorder	January 2020
naloxone nasal spray	N/A	Insys	Opioid overdose	March 2020
ET-105 (lamotrigine)	N/A	Eton Pharmaceuticals	Seizures	March 2020
rizatriptan, oral film	Rizaport™	IntelGenx	Migraine	March 2020
E-58425 (tramadol 44mg and celecoxib 56mg tablet)	N/A	Esteve Pharmaceuticals	Pain	March 2020
fenfluramine, ZX008	Fintepla™	Zogenix	Seizures associated with Dravet syndrome	March 2020
ferric pyrophosphate citrate	Triferic IV™	Rockwell Medical	Iron replacement	March 2020
opicapone	Ongentys™	Neurocrine Biosciences	Parkinson's disease	April 2020
dasotraline	N/A	Sunovion	Binge eating disorder	May 2020
L-lactic acid, citric acid, and potassium bitartrate	Amphora™	Evoform	Pregnancy prevention	May 2020
FMX103 (minocycline foam 1.5%)	N/A	Foamix Pharmaceuticals	Severe papulopustular rosacea	June 2020
metoclopramide nasal spray	Gimoti™	Evoke Pharma	Diabetic gastroparesis	June 2020
fosfomycin for injection	Contepo™	Nabriva Therapeutics PLC	cUTI	April 2020
RVL-1201 (oxymetazoline ophthalmic solution 0.1%)	N/A	Vertical Pharmaceuticals (Osmotica)	Acquired blepharoptosis (droopy eyelid)	July 2020
calcipotriene 0.005% and betamethasone 0.064% cream	Wynzora™	MC2 Therapeutics	Plaque psoriasis	July 2020
cantharidin 0.7% topical solution	Ycanth™	Verrica Pharmaceuticals	Molluscum contagiosum	July 2020
donepezil, transdermal	Adlarity™	Corium	Alzheimer's dementia	July 2020
veverimer	N/A	Tricida	Metabolic acidosis in patients with chronic kidney disease (CKD)	August 2020
clascoterone	Winlevi™	Cassiopea SPA	Acne	August 2020
oliceridine	Olinvo™	Trevena	Pain	August 2020
diazepam buccal film	Libervant™	Aquestive Therapeutics	Seizures	September 2020
ALKS 3831 (olanzapine and samidorphan)	N/A	Alkermes	Schizophrenia	November 2020
daxibotulinumtoxinA	N/A	Revance Therapeutics	Frown lines	November 2020

FIRST GENERIC LAUNCHES OF TOP SELLING BRAND NAME DRUGS IN THE PAST TWELVE MONTHS

GENERIC NAME	BRAND NAME	BRAND MANUFACTURER	INDICATION(S)	DATE APPROVED*
travoprost ophth soln.	Travatan Z®	Alcon Novartis	Glaucoma or ocular hypertension	December 2019
everolimus+	Afinitor®	Novartis	Certain forms of cancer	December 2019
etonogestrel/ ethinyl estradiol	NuvaRing®	Organon	Pregnancy prevention	December 2019
deferasirox+	Jadenu®	Novartis	Iron overload	November 2019
fosaprepitant dimeglumine	Emend®	Merck Sharp & Dohme	Chemotherapy-induced nausea and vomiting	September 2019
posaconazole	Noxafil®	Merck Sharp & Dohme	Fungal infections	September 2019
pregabalin	Lyrica®	Pfizer	Neuropathic pain, and seizures	July 2019
erlotinib+	Tarceva®	Genentech	Lung cancer	May 2019
loteprednol etbonate	Lotemax®	Bausch Health	Allergic conjunctivitis	May 2019
solifenacin	Vesicare®	Astellas	Incontinence	April 2019

*Date usually indicates FDA approval date. The product's launch date is determined by the manufacturer. Generic approvals that do not come to market within three months of approval are listed and dated when they enter the market.

+Specialty medication

OTHER FIRST GENERIC LAUNCHES IN THE PAST TWELVE MONTHS

GENERIC NAME	BRAND NAME	MANUFACTURER	INDICATION(S)	DATE APPROVED*
gadoterate meglumine	Clariscan®	Guerbet	Contrast agent	March 2020
everolimus+	Zortress®	Novartis	Transplant	March 2020
ziprasidone inj	Geodon®	Pfizer	Schizophrenia	March 2020
azelastine/fluticasone	Dymista®	Mylan Specialty	Seasonal allergic rhinitis	March 2020
naproxen/esomeprazole DR	Vimovo®	Horizon Therapeutics USA	Arthritis	February 2020
phenobarbital inj	Phenobarbital inj®	Hikma	Seizures	February 2020
strontium-89 chloride inj	Metastron inj®	GE Health Care	Bone pain	February 2020
irinotecan inj	Camptosar inj®	Pfizer	Colorectal cancer	February 2020
moxifloxacin ophth soln	Moxeza®	Novartis	Conjunctivitis	February 2020
potassium chloride ER tab	K-tab®	Abbvie	Hypokalemia	January 2020
penicillamine tab	Depen Titratabs®	Meda Pharmaceuticals Mylan	Cystinuria hepatic encephalopathy, Wilson's disease	January 2020
amphetamine ER susp	Adzenys ER suspension®	Neos Therapeutics	Attention deficit hyperactivity disorder	December 2019

continued

OTHER FIRST GENERIC LAUNCHES IN THE PAST TWELVE MONTHS *(continued)*

GENERIC NAME	BRAND NAME	MANUFACTURER	INDICATION(S)	DATE APPROVED*
hydrocodone bitartrate 12 hr abuse-deterrent	Zohydro ER caps [®]	Pernix Therapeutics	Pain	December 2019
doxepin hcl	Silenor [®]	Somaxon Pharmaceuticals	Insomnia	December 2019
sulconazole nitrate cream, 1%	Exelderm cream [®]	Ranbaxy Pharmaceuticals	Tinea corporis, tinea pedis	December 2019
sulconazole nitrate solution, 1%	Exelderm soln [®]	Ranbaxy Pharmaceuticals	Tinea corporis, tinea pedis	December 2019
dapsone gel, 7.5%	Aczone 7.5% [®]	Allergan	Acne	December 2019
sucralfate suspension	Carafate [®]	Forest/Allergan	Ulcers	December 2019
pentamidine	Nebupent [®]	Seton Pharmaceuticals	Serious lung infections	December 2019
mesalamine ER	Apriso [®]	Bausch Health	Ulcerative colitis	December 2019
ciprofloxacin/fluocinolone otic	Otovel [®]	Arbor Pharmaceuticals	Ear infections	November 2019
ivermectin cream, 1%	Soolantra [®]	Galderma	Rosacea	October 2019
aminocaproic acid oral syrup	Amicar [®]	Clover Pharmaceuticals	Hemostasis	September 2019
triamterene	Dyrenium [®]	Concordia	Edema	September 2019
halcinonide	Halog [®]	Ranbaxy	Itchy skin	August 2019
ramelteon	Rozerem [®]	Takeda	Insomnia	August 2019
icatibant injection+	Firazyr [®]	Shire/Takeda	HAE	July 2019
daptomycin injection	Daptomycin [®]	Sagent/Xelia	Complicated bacterial infections	July 2019
carboprost injection	Hemabate [®]	Pfizer	Termination of pregnancy	July 2019
febuxostat	Uloric [®]	Takeda	Hyperuricemia in patients with gout	July 2019
doxylamine/pyridoxine DR	Diclegis [®]	Duchesnay	Nausea and vomiting in pregnancy	June 2019
naftifine gel, 1%	Naftin gel [®]	Amneal Pharmaceuticals	Fungal infections	June 2019
sildenafil for suspension+	Revatio [®]	Pfizer	Pulmonary arterial hypertension	June 2019
mifepristone	Mifeprex [®]	Dance Laboratories	Termination of pregnancy	May 2019
bosentan+	Tracleer [®]	Actelion Pharmaceuticals	Pulmonary hypertension	May 2019
mesalamine	Delzicol [®]	Allergan	IBD	May 2019
penicillamine+	Cuprimine [®]	Bausch Health	Hepatic encephalopathy & Wilson's disease	May 2019
valrubicin+	Valstar [®]	Endo	Bladder cancer	April 2019
ambrisentan+	Letairis [®]	Gilead Sciences	Pulmonary arterial hypertension	April 2019
aliskiren	Tekturna [®]	Noden Pharma USA	Hypertension	April 2019

*Date usually indicates FDA approval date. The product's launch date is determined by the manufacturer. Generic approvals that do not come to market within three months of approval are listed and dated when they enter the market.

+Specialty medication

GENERICS OF TOP SELLING BRAND DRUGS POTENTIALLY AVAILABLE SOON

GENERIC NAME	BRAND NAME	MANUFACTURER	INDICATION(S)	DATE APPROVED*
ascorbic acid; PEG; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	Moviprep®	SalixValeant	Osmotic laxative	2020
tolvaptan+	Samsca®	Otsuka	Hypernatremia	2020
albuterol sulfate	Proventil® HFA/ ProAir® HFA	Merck/Teva	Asthma/COPD	2020
difluprednate	Durezol®	Alcon/Novartis	Eye inflammation	2020
exenatide	Byetta®	AstraZeneca	Diabetes	2020
teriparatide+	Forteo®	Lilly	Osteoporosis	2020
topiramate	Qudexy XR®	Upsher-Smith	Seizures	2020
ethinyl estradiol	Taytulla®	Allergan	Pregnancy prevention	2020
varenicline Tartrate	Chantix®	Pfizer	Smoking cessation	May 2020
mometasone/formoterol fumarate	Dulera®	Merck & Co	Asthma	November 2020
vilazodone hydrochloride	Viibryd®	Forest	Depression	2021
fluticasone propionate	Flovent®	GSK	Respiratory	2021
nebivolol	Bystolic®	Allergan	Hypertension	2021
dabigatran	Pradaxa®	Boehringer Ingelheim Pharmaceuticals	Anticoagulant	2021

* Expected to market dates are predictions made by Prime based on industry information.

+ Specialty medication

REFERENCES

- <https://www.empr.com/home/news/anjeso-approved-for-management-of-moderate-to-severe-pain/>
- <https://www.bioworld.com/articles/433229-angle-of-ketorolac-attack-yakked-as-baudax-hails-anjeso-pesos>
- <https://ir.agiletherapeutics.com/news-releases/news-release-details/fda-approves-agile-therapeutics-incs-twirlar-levonorgestrel-and>
- <https://www.empr.com/home/news/fda-panel-votes-in-favor-of-contraceptive-patch-despite-concerns-over-efficacy/>
- <https://www.fool.com/investing/2020/02/19/is-agile-therapeutics-stock-a-buy-after-its-big-fd.aspx>
- <https://americanheadachesociety.org/news/eptinezumab-vyepti-approved-by-fda/>
- <https://scrip.pharmintelligence.informa.com/SC141734/Pricing-Could-Help-Lundbecks-Vyepti-In-SlowGrowing-CGRP-Market>
- <https://www.globenewswire.com/news-release/2020/02/21/1988825/0/en/Esperion-Announces-FDA-Approval-of-NEXLETOL-bempedoic-acid-Tablet-an-Oral-Once-Daily-Non-Statins-LDL-Cholesterol-Lowering-Medicine.html>
- <https://www.fiercepharma.com/marketing/esperion-notches-2nd-fda-approval-cholesterol-lowering-combo-nexlizet>
- <https://www.globenewswire.com/news-release/2020/02/26/1991460/0/en/Esperion-Announces-FDA-Approval-of-the-NEXLIZET-bempedoic-acid-and-ezetimibe-Tablet-an-Oral-Once-Daily-Non-Statins-LDL-Cholesterol-Lowering-Medicine.html>
- <https://www.globenewswire.com/news-release/2020/02/27/1991526/0/en/Acacia-Pharma-Announces-US-FDA-Approval-of-BARHEMSYS-amisulpride-for-the-Treatment-and-Prevention-of-Postoperative-Nausea-and-Vomiting-PONV.html>
- <https://www.biohavenpharma.com/investors/news-events/press-releases/02-27-2020>
- https://icer-review.org/announcements/acute_migraine_evidence_report/
- <https://www.biohavenpharma.com/investors/news-events/press-releases/03-12-2020>
- <https://www.allergan.com/News/Details/2020/03/Allergan%20Receives%20FDA%20Approval%20for%20DURYSTA%20bimatoprost%20implant%20the%20First%20and%20Only%20Intracameral%20Biode>

All brand names are property of their respective owners.